Analystreport

Amicus Therapeutics (NASDAQ: FOLD) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $22.00 price target on the stock.

Amicus Therapeutics, Inc.  (FOLD) 
Last amicus therapeutics, inc. earnings: 11/11 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.amicusrx.com/investor-relations